Tag Archives: Pharmaceutical

News

The future of reaction screening is here

Laboratory technology developer Technobis has released ReactALL™, an innovative benchtop multiple reactor system for medium throughput experimentation, helping scientists tap into the under-utilized nights and weekends. Available globally now, ReactALL™ uses novel integrated automated sampling technology to accelerate chemical reaction screening, optimisation, route scouting, reaction profiling and kinetics. ReactALL™ addresses the gap between high throughput and low throughput screening to provide high-quality, data rich results with low material needs.

Technobis’ new instrument, developed with scientific input from Pfizer, uses proprietary SmartCap™ technology to sample, quench and dilute directly into commercial standard HPLC (high performance liquid chromatography) vials. Reaction setup is fast, taking less than 30 minutes with ReactALL™.

The system comprises five small-scale reactors, each equipped with fully automated sampling. Representative samples are immediately quenched, diluted, and transferred to standard HPLC vials on the ReactALL™. The sample and dilution volumes are precisely controlled by the system for quantitative analysis. Wide bore tubing and streamlined pump-free fluidics assure robust sample transfer, even for heterogeneous samples. And the novel SmartCap™ sampling technology does not pierce reactor septa, so there are no pierced holes for losing solvent.

Accelerating in-depth chemical understanding is a key goal of the ReactALL™. Such data-rich experiments can translate to significant time saving, and thus money. Screening reactions for the best reagents, catalysts and conditions; optimising reaction yield, selectivity and impurity control; mechanistic profiling; ReactALL™ obtains high quality results early in drug development to allow chemists to draw the right conclusions, as early as possible.

“A guiding ethos at Technobis is ‘Help research succeed’”, explained John de Kok, CEO of Technobis. “ReactALL™ will transform the way chemists conduct medium throughput research and in the pharmaceutical industry, which is close to my heart, bring medicines to market faster than ever before.”

ReactALL™ possesses multiple features that enhance reaction scientists’ investigation capabilities. Colour cameras, integrable Raman spectroscopy probes, provide crucial information on physical and chemical state changes, such as dissolution and precipitation, colour changes, and much more. ReactALL™ uses overhead stirring design specifically with the aid of Computational Fluid Dynamics to closely recreate mixing properties conferred by mechanical agitators, and poorly captured by magnetic stir bars.

“It’s essential that ReactALL™ fits into the lab of the future and industry 4.0 compatibility is key there,” said Stephan van Banning, chief technology officer at Technobis. “Our software engineers have enabled interoperability with pretty much anything you might want in your workflow.”

For example, ReactALL™ could run reactions and automatically take, quench and dilute samples into HPLC vials. A pre-loaded SmartCap™ can be loaded in ReactALL™ while a robotic arm could then transport your sample vial trays to the HPLC machine. The chemist would need only 30 minutes for setting up the reactions and the next day, they already have the HPLC data.

To learn more about how ReactALL™ can help your laboratory workflow step into the future, visit the launch page here: https://www.crystallizationsystems.com/products/reactall

Appointments, News

Evaluate appoints Matthew Wright as Chief Financial Officer

London, UK and Boston, MA – 11 May 2022 – Evaluate, a leading provider of market intelligence and predictive analytics for the pharmaceutical industry, has today announced that it has appointed Matthew Wright as Chief Financial Officer. Wright will work closely with both the Evaluate and Norstella executive and finance teams as the newly merged organisation combines as a $1.6 billion global pharma commercial intelligence provider.

Wright commented: “This is a really exciting time to join the business as it comes together to build a comprehensive data, insight and intelligence solution that will inform and support the industry across the entire drug lifecycle from pipeline to patient.

“I look forward to working with the leadership team to further extend our reach so that we can make an even greater contribution to those that are bringing new drugs to market and help patients gain access to life-saving therapies, faster,” he said.

Wright has over 15 years’ experience as a seasoned executive, providing financial analysis of performance, growth and acquisition opportunities and strategic decision support to senior leadership teams. He joins Evaluate from Informa Intelligence where he was most recently Finance Director for Pharma and Financial. He previously held similar roles at TNT Express and Ascential and brings complementary knowledge of high value B2B subscription business to Evaluate.

Lucy Ralph, CAO of Evaluate, added: “We have ambitious growth plans for the future as a newly merged business. We are determined to build on our success to date by offering an end-to-end view of the pharmaceutical market landscape and I’m confident that Matt will play a central role in helping us to grow as a business.”

News

Bachem begins building its biggest ever production facility as Switzerland celebrates National Future Day

Bachem, the Swiss-based biotechnology and pharmaceutical company, began laying the foundations for its biggest production site so far. The plant, in Bubendorf, Switzerland, will expand Bachem’s manufacturing capacity and provide the world’s most modern facility for producing peptides and oligonucleotides by 2024.

This project will secure the leading position of the Bubendorf site as a centre of excellence for producing active pharmaceutical ingredients. Bachem will be able to increase its production in compliance with GMP standards and supply even more high-quality pharmaceutical ingredients to the global market. This move will also confirm the company’s commitment to its Swiss roots, creating 150 new highly skilled jobs in the first phase alone.

Bachem is responding to increases in demand for its products around the world by expanding its productive capability. The Bubendorf and Vionnaz sites in Switzerland have received an investment of more than 150 million Swiss francs, which has led to the creation of over 400 new jobs. With available land at the Bubendorf site likely to run out in the relatively near future, the hunt for a new Swiss site has begun.

The foundation stone at the new facility was laid on Switzerland’s National Future Day. Bachem marked this event by inviting young people along for educational visits, to tour the facility and participate in chemistry experiments in the training laboratory, with supervision from their apprentices.

Thomas Meier, CEO at Bachem, said:

“I am delighted that we are commencing the construction of our largest production plant to date on National Future Day. Today has a special symbolism for Bachem. We are a company with a long-term mindset. Our success is founded on our ability to invest into our company efficiently and with foresight, but also on the ability to excite new generations with the impact chemistry and the natural sciences can have.”